{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:43:07Z","timestamp":1789011787113,"version":"build-2803163510"},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>B-cell (B-PLL) and T-cell (T-PLL) prolymphocytic leukemias are rare, poor-prognosis lymphoid neoplasms with similar presentation characterized by symptomatic splenomegaly and lymphocytosis. They can be distinguished from each other and from other T- and B-cell leukemias by careful evaluation of morphology, immunophenotyping, and molecular genetics. The clinical behavior is typically aggressive, although a subset of patients may have an indolent phase of variable length. First-line therapy for T-PLL is with intravenous alemtuzumab and for B-PLL is with combination purine analog-based chemo-immunotherapy. New B-cell receptor inhibitors, such as ibrutinib and idelalisib, may have a role in the management of B-PLL, especially for the patients harboring abnormalities of TP53. Allogenic stem cell transplantation should still be considered for eligible patients and may be the only current therapy capable of delivering a cure. In the past few years, many of the molecular mechanisms underlying disease pathogenesis and progression have been revealed and are likely to lead to the development of novel targeted approaches.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.361","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:23:25Z","timestamp":1473938605000},"page":"361-367","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Management of prolymphocytic leukemia"],"prefix":"10.1182","volume":"2015","author":[{"given":"Claire","family":"Dearden","sequence":"first","affiliation":[{"name":"Department of Haemato-Oncology, Royal Marsden Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7823","key":"2019111521084528200_B1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","article-title":"Prolymphocytic leukaemia of B and T cell type","volume":"2","author":"Catovsky","year":"1973","journal-title":"Lancet"},{"key":"2019111521084528200_B2","article-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"12","key":"2019111521084528200_B3","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"6","key":"2019111521084528200_B4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pbc.25336","article-title":"A pediatric case of T-cell prolymphocytic leukemia","volume":"62","author":"Mitton","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111521084528200_B5","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1097\/MPH.0000000000000317","article-title":"A \u03b3\/\u03b4 T-cell receptor prolymphocytic leukemia and CD4\u2212\/CD8\u2212 double-negative immunophenotype in a pediatric patient","volume":"37","author":"Moser","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"2019111521084528200_B6","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"key":"2019111521084528200_B7","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1038\/oncsis.2013.30","article-title":"Proto-oncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo","volume":"2","author":"Hashimoto","year":"2013","journal-title":"Oncogenesis"},{"issue":"3","key":"2019111521084528200_B8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gcc.1141","article-title":"A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia","volume":"31","author":"Soulier","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111521084528200_B9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Bellanger","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111521084528200_B10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111521084528200_B11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/gcc.22141","article-title":"Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia","volume":"53","author":"Bergmann","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2019111521084528200_B12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.leukres.2014.08.015","article-title":"Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia","volume":"38","author":"Kawai","year":"2014","journal-title":"Leukemia Res"},{"issue":"6","key":"2019111521084528200_B13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 abnormalities in B-cell prolymphocytic leukaemia","volume":"89","author":"Lens","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111521084528200_B14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1309\/AJCPUBHM8U7ZFLOB","article-title":"Aberrations of MYC are a common event in B-cell prolymphocytic leukemia","volume":"142","author":"Flatley","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111521084528200_B15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3960\/jslrt.54.219","article-title":"B-cell prolymphocytic leukemia carrying t(8;14)(q24;q32), associated with both autoimmune hemolytic anemia and pure red cell aplasia","volume":"54","author":"Iioka","year":"2014","journal-title":"J Clin Exp Hematop"},{"issue":"11","key":"2019111521084528200_B16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2009.137","article-title":"B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures","volume":"23","author":"Del Guidice","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111521084528200_B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","article-title":"B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma","volume":"124","author":"van der Velden","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111521084528200_B18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111521084528200_B19","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111521084528200_B20","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of Pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111521084528200_B21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","article-title":"Phase I trial of nelarabine in indolent leukemia","volume":"26","author":"Ghandi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111521084528200_B22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.13175","article-title":"Bendamustine is effective in T-cell prolymphocytic leukaemia","volume":"168","author":"Herbaux","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111521084528200_B23","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential therapy of fludarabine, mitoxantrone and cyclophosphamide (FMC) induction followed by alemtuzumab consolidation is effective and safe in patients with T-cell prolymphocytic leukemia (T-PLL)\u2014results from a multicentre phase II trial of the German CLL study group (GCLLSG)","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"issue":"32","key":"2019111521084528200_B24","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111521084528200_B25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-008-0541-5","article-title":"A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia","volume":"88","author":"Tempescul","year":"2009","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111521084528200_B26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","article-title":"Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"87","author":"Chow","year":"2011","journal-title":"Eur J Haematol"},{"issue":"12","key":"2019111521084528200_B27","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111521084528200_B28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","article-title":"Complete response to Alemtuzumab in a patient with B prolymphocytic leukaemia","volume":"82","author":"Chaar","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111521084528200_B29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111521084528200_B30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111521084528200_B31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111521084528200_B32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-cell prolymphocytic leukemia (T-PLL): a retrospective study from the European Group for Blood and Marrow Transplantation (EBMT) and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111521084528200_B33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem celltransplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111521084528200_B34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12185-014-1678-8","article-title":"Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy","volume":"100","author":"Szuszies","year":"2014","journal-title":"Int J Hematol"},{"issue":"12","key":"2019111521084528200_B35","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bmt.1704991","article-title":"Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: long term follow-up","volume":"35","author":"Castagna","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111521084528200_B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111521084528200_B37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12185-014-1505-2","article-title":"Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission","volume":"99","author":"Arima","year":"2014","journal-title":"Int J Hematol"},{"issue":"293","key":"2019111521084528200_B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaa5079","article-title":"Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia","volume":"7","author":"Hasanali","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/361\/1250674\/bep00115000361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/361\/1250674\/bep00115000361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:44:12Z","timestamp":1573861452000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/361\/306121\/Management-of-prolymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.361","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}